Related Experiment Video
Updated: Jul 4, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Congenital angiosarcoma with transient response to paclitaxel
Amy B Good1, Antonio Nascimento, Kirk M Welker
1Department of Pediatrics, Mayo Clinic and Foundation, Rochester, MN, USA. good@bcm.edu
Journal of Pediatric Hematology/Oncology
|June 6, 2008
Summary
We present the first known case of congenital angiosarcoma, a rare cancer with a poor outlook. Paclitaxel showed a temporary response, suggesting its potential use in treating unresectable angiosarcoma.
Area of Science:
- Pediatric Oncology
- Vascular Malignancies
Background:
- Angiosarcoma is a rare vascular cancer with a generally poor prognosis.
- Congenital cases are exceptionally rare, with limited understanding of their behavior and treatment.
Observation:
- This report details the first documented case of congenital angiosarcoma.
- The infant presented with a rapidly growing vascular tumor.
Findings:
- The congenital angiosarcoma exhibited a transient positive response to paclitaxel treatment.
- Paclitaxel, a chemotherapy agent, demonstrated potential efficacy in managing this rare malignancy.
Implications:
- This case highlights the possibility of congenital angiosarcoma and its unique clinical course.
- Paclitaxel may represent a therapeutic option for unresectable or congenital angiosarcoma, warranting further investigation.
